<DOC>
	<DOCNO>NCT02964143</DOCNO>
	<brief_summary>Platelet-rich plasma ( PRP ) autologous product prepare patient 's blood , represent powerful source platelet-derived growth factor , particularly useful field regenerative medicine . The active sequential secretion growth factor induce different cell signal cascade activate angiogenesis , cell proliferation , cell differentiation , eventually lead new matrix synthesis tissue regeneration . The potential benefit use PRP treatment cartilage defect rely number study conduct validate animal model vitro , demonstrate ability PRP stimulate collagen production proteoglycans synthesis , well proliferation differentiation mesenchymal stem cell chondrocytes . Additionally , increase number clinical study show improvement symptom , especially pain , without occurrence serious adverse event . Hyaluronic acid ( HA ) , one major component synovial fluid surround cartilage , assume important role viscoelastic property articular cartilage , confer shock absorb lubricating function . It demonstrate rheological property synovial fluid decrease age patient suffer osteoarthritis . Nowadays , intra-articular injection hyaluronic acid represent well recommend therapeutic option relieve osteoarthritic symptom , confer mechanical action joint structure , thus lead reduce pain improve joint function Based data , seem reasonable hypothesize combination PRP hyaluronic acid could provide great benefit compare administration product alone , effect osteoarthritis improvement base different mechanism action . In fact , one side PRP promote cartilage regeneration , side HA act 3-dimensional support mesh PRP , provide optimal release platelet growth factor , strengthen extending time activity PRP . Cellular MatrixTM CE-marked class III medical device manufacture Swiss company RegenLab SA . Cellular MatrixTM allow prepare autologous PRP combine non-crosslinked hyaluronic acid safe , rapid manner single step . The PRP/HA combination intend injected intra-articularly , order relieve osteoarthritic symptom improve joint mobility function . Therefore , PRP/HA combination might represent novel therapeutic option patient suffer knee osteoarthritis . This study evaluate whether effect PRP/HA combination prepare Cellular MatrixTM inject intra-articularly treatment mild moderate knee osteoarthritis , superior term mechanism action , compare well-recognized hyaluronic acid treatment ( Ostenil® Plus ) .</brief_summary>
	<brief_title>Clinical Investigation Compare Safety Efficacy Cellular Matrix Those Ostenil® Plus</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Symptomatic knee osteoarthritis unilateral knee , characterize pain walking ( WOMAC A1 score assess previous 24 hour 100mm VAS : 50 ≤ WOMAC A1 ≤ 90 ) reduce joint function ( total WOMAC C score assess previous 24 hour 100mmVAS : 50 ≤ WOMAC A1 ≤ 90 ) Femorotibial knee osteoarthritis define accord ACR criterion Bilateral knee osteoarthritis allow , provide contralateral knee characterize maximum pain 30 0 100 mm scale n't require systemic analgesic treatment , exception paracetamol maximum dose 4 g per day Radiographic femorotibial knee osteoarthritis ( radiograph old 3 month ) Kellgren &amp; Lawrence grade IIIII Outpatient capable walk 50 meter without assistance Signature inform consent form Capable understanding study 's imperative , well write instruction Capable fillingout evaluation questionnaire Radiographic femorotibial knee osteoarthritis Kellgren &amp; Lawrence grade I IV Bilateral knee osteoarthritis , characterize pain great 30 knee evaluate 0 100mm scale require systemic analgesic treatment paracetamol great 4g/ day Viscosupplementation past 3 month Corticosteroid injection past 3 month PRP PRP/HA injection past 12 month Any surgery knee plan next 6 month Systematic use corticosteroid ( except inhale ) level III analgesic past 3 month NSAID past month Treatment slowacting antirheumatic drug ( diacerhein , soybean avocado unsaponifiables , chondroitin sulfate , glucosamine ) start past 6 month History allergy hyaluronic acid Autoimmune disease ( rheumatoid arthritis , lupus ) Surgery affect knee past 3 month Infection affect knee past 6 month Rheumatologic disorder arthritis Clinical evidence local inflammation redness heat joint Any knee surgery plan within 6 month Hereditary acquire hematologic clotting disorder , drepanocytosis , platelet dysfunction , thrombocytopenia ( &lt; 150'000 platelets/mm3 ) , etc . Anemia ( Hemoglobin &lt; 10g/dl ) Anticoagulant treatment ( patient antiaggregant treatment take part study long clotting time ( CT ) within reference value ) Acute infection Malignant disease ( especially bone hematological ) Recent fever serious disorder ( cardiovascular pathology , active gastroduodenal ulcer , digestive hemorrhage , liver disease , etc . ) Patient renal impairment ( creatinine clearance 45 ml / min ) Patient liver failure , pending recently receive liver transplant Infectious diseases Pregnancy breastfeed plan pregnancy course study Immunosuppression Insulindependent diabetic patient Participation ongoing past 3 month another clinical study Participation another osteoarthritis clinical study past year Refusal sign inability give Informed Consent Patient unable submit constraint protocol , include patient whose mental condition allow understand nature , objectives possible consequence study Any reason , opinion investigator , may interfere proper conduct study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>